Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism | Zendy

Lucie Paloque | Zendy; Benoît Witkowski | Zendy; Joël Lelièvre | Zendy; Manel Ouji | Zendy; Tanila Ben Haddou | Zendy; Frédéric Ariey | Zendy; Anne Robert | Zendy; JeanMichel Augereau | Zendy; Didier Ménard | Zendy; Bernard Meunier | Zendy; Françoise Benoît-Vical | Zendy

Open Access

Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism

Author(s) -

Lucie Paloque,

Benoît Witkowski,

Joël Lelièvre,

Manel Ouji,

Tanila Ben Haddou,

Frédéric Ariey,

Anne Robert,

JeanMichel Augereau,

Didier Ménard,

Bernard Meunier,

Françoise Benoît-Vical

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx412

Subject(s) - artemisinin , plasmodium falciparum , biology , drug resistance , artemether , cross resistance , lineage (genetic) , malaria , dihydroartemisinin , genetics , gene , immunology

Owing to the emergence of multiresistant Plasmodium falciparum parasites in Southeast Asia, along with the impressive decrease in the efficacy of the endoperoxide compound artemisinin and of artemisinin-based combination therapies, the development of novel antimalarial drugs or combinations is required. Although several antiplasmodial molecules, such as endoperoxide-based compounds, are in advanced research or development, we do not know whether resistance to artemisinin derivatives might impact the efficacy of these new compounds.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research